Operator
Greetings and welcome to TG Therapeutics Q1 2021 Earnings Conference Call and Business Update. [Operator Instructions] I would now like to turn the conference over to Jenna Bosco, Senior VP of Corporate Communications. Please proceed.
Jenna Bosco
Senior Vice President, Corporate Communications
Thank you. Welcome, everyone, and thanks for joining us this morning. I m Jenna Bosco, and with me today to discuss the first quarter 2021 financial results and provide a business update are Michael Weiss, our Executive Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer. Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments as well as an update on our current pivotal programs and key goals for 2021, Adam will provide an update on our commercialization efforts, and Sean will provide a brief overview of our financial results before turning the call o
Venous thromboembolism
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Latest Trends in the Management of Pulmonary Embolism
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
frontMIND Study Evaluating Tafasitamab Combination as a
First-line Treatment for Diffuse Large B-Cell Lymphoma
PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3
frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation.